- MESO · Nasdaq
- Biological Products, (No Diagnostic Substances)
- Melbourne, Victoria, C3
- 108 employees
- CIK 0001345099
Updated from SEC filings through
Top things to know
Executives
- Silviu Itescu CEO and Managing Director Form 3, April 1, 2026
- James Michael Obrien Chief Financial Officer Form 4, July 9, 2026
- Eric Allen Rose Chief Medical Officer,Director Form 3, March 18, 2026
Mesoblast Ltd is a U.S. public company in biological products, (no diagnostic substances) (SIC 2836), headquartered in Melbourne, Victoria, C3. It trades as MESO on Nasdaq. Revenue was $17.2M in the fiscal year ending June 30, 2025, +191.4% from the year before. It reported about 108 employees.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $17.2M 20-F, 2025-08-29 | $5.9M 20-F, 2025-08-29 | $7.5M 20-F, 2025-08-29 | $10.2M 20-F, 2024-08-29 | $7.4M 20-F, 2023-08-31 |
| Operating income | Not on file | Not on file | Not on file | Not on file | Not on file |
| SG&A | Not on file | Not on file | Not on file | Not on file | Not on file |
| Net income | -$102M 20-F, 2025-08-29 | -$88.0M 20-F, 2025-08-29 | -$81.9M 20-F, 2025-08-29 | -$91.3M 20-F, 2024-08-29 | -$98.8M 20-F, 2023-08-31 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Silviu Itescu founder at mesoblast | CEO and Managing Director | Form 3, April 1, 2026 |
| James Michael Obrien | Chief Financial Officer | Form 4, July 9, 2026 |
| Eric Allen Rose | Chief Medical Officer,Director | Form 3, March 18, 2026 |
What Mesoblast Ltd does
Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company’s proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process.
Press release "About" paragraph, 10-K for the year ending October 29, 2026
Shares and governance
| Shares outstanding | 1.30 billion (as of June 30, 2026) | 20-F, August 27, 2026 |
|---|---|---|
| Auditor | PricewaterhouseCoopers (Melbourne, Australia) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| April 10, 2026 | Gregory George Director | Buy | 7,910,962 | $11.4M | Form 4, April 13, 2026 |
| April 10, 2026 | Gregory George Director | Buy | 8,305,962 | $26.1M | Form 4, April 10, 2026 |
Recent 8-K events
No 8-K filings on file.
Frequently asked questions about Mesoblast Ltd
- What does Mesoblast Ltd do?
- In its own words, from Item 1 of its 10-K: "Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company’s proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process."
- What is Mesoblast Ltd's revenue?
- $17.2M for the fiscal year ending June 30, 2025, from its 20-F filed August 29, 2025.
- Is Mesoblast Ltd profitable?
- Mesoblast Ltd reported net income of -$102M for the fiscal year ending June 30, 2025.
- How many employees does Mesoblast Ltd have?
- About 108 as of June 30, 2026, as stated in its annual report.
- Who is the CFO of Mesoblast Ltd?
- James Michael Obrien, Chief Financial Officer, as named in a 4 filed July 9, 2026.
- Where is Mesoblast Ltd headquartered?
- Melbourne, Victoria, C3.
- What is Mesoblast Ltd's stock ticker?
- MESO, MEOBF on Nasdaq.
- What industry is Mesoblast Ltd in?
- Biological Products, (No Diagnostic Substances), SIC code 2836.
- What is Mesoblast Ltd's website?
- mesoblast.com.
- Is Mesoblast Ltd a public company?
- Yes. Mesoblast Ltd files with the SEC under CIK 0001345099 and trades as MESO.
- Who audits Mesoblast Ltd?
- PricewaterhouseCoopers, Melbourne, Australia, as named in its latest annual report (10-K).
- How many shares of Mesoblast Ltd are outstanding?
- 1.30 billion shares as of June 30, 2026, from its 20-F filed August 27, 2026.
- Have Mesoblast Ltd insiders traded stock recently?
- Since April 10, 2026, officers and directors reported 0 open-market sales and 2 purchases worth about $37.5M on Forms 4 and 5. The most recent: Gregory George (Director) bought 7,910,962 shares on April 10, 2026.